Lilly sells R&D campus to Covance in the pioneering deal.

Lilly sells R&D campus to Covance in the pioneering deal..


Yesterday, Eli Lilly made a significant step toward outsourcing with the sale of a significant R&D site to contract research group Covance and the formation of new contracts with Quintiles and i3. 


Lilly is adopting a road that is less usual in R&D but is already well-trodden in the pharmaceutical manufacturing industry. When faced with excess capacity, several pharmaceutical companies chose to sell off operations, frequently including legacy contracts, to management buyout teams or reputable contract manufacturers.

The Lilly/Covance deal is one of the first large-scale examples of this type of facility sale in early-stage drug development – a function that until recently was jealously guarded within the walls of big pharma companies. 

According to the terms of the agreement, Covance will offer jobs to 260 Lilly employees who work in non-Good Laboratory Practice (GLP) toxicology, in vivo pharmacology, quality control laboratory, and imaging services. Covance said it plans to upgrade the site and will "double or even triple" the workforce.

Comments

Popular posts from this blog

 Role of Blockchain in Healthcare Data Management

Demystifying AI in Drug Discovery: Transforming Pharma R&D

GREEN INITIATIVES IN INDIA : Sustainable Practices in Pharmaceuticals